Valiente, ManuelAhluwalia, Manmeet SBoire, AdrienneBrastianos, Priscilla KGoldberg, Sarah BLee, Eudocia QLe Rhun, EmiliePreusser, MatthiasWinkler, FrankSoffietti, Riccardo2024-12-102024-12-102018-03Trends Cancer . 2018 Mar;4(3):176-196https://hdl.handle.net/20.500.12105/25875We thank members of our laboratories for helpful discussions. We are grateful for funding from the National Cancer Institute 2P30CA008748-48, to A.B.), Mundipharma (E.L.R.), Amgen (E.L.R.), German Cancer Aid (Deutsche Krebshilfe), Translational Oncology Program, the Prevent Brain Metastasis Consortium (F.W.), MINECO-Retos (SAF2014-57243-R, to M.V.), MINECO-Europa Excelencia (SAF2015-62547-ERC, to M.V.), IX FERO Grant for Research in Oncology (M.V.), Bristol-Myers Squibb Melanoma Research Alliance Young Investigator Award 2017 (M.V.), and the Beug Foundation Prize for Metastasis Research 2017 (M.V.). M.V. is a Ramon y Cajal Investigator (RYC-2013-13365).Metastasis, involving the spread of systemic cancer to the brain, results in neurologic disability and death. Current treatments are largely palliative in nature; improved therapeutic approaches represent an unmet clinical need. However, recent experimental and clinical advances challenge the bleak long-term outcome of this disease. Encompassing key recent findings in epidemiology, genetics, microenvironment, leptomeningeal disease, neurocognition, targeted therapy, immunotherapy, and prophylaxis, we review preclinical and clinical studies to provide a comprehensive picture of contemporary research and the management of secondary brain tumors.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/brain metastasisgenomicsmicroenvironmentneurocognitionpreventiontherapyAttribution-NonCommercial-NoDerivatives 4.0 International2950666943176-196Trends in Cancerhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6602095/pdf/nihms-1037277.pdfopen access